Number of Participants Relapsed
Primary
· 3 months after last rTMS treatment
Rate of stimulant use relapse compared between active vs. sham rTMS groups
| Group | Value | 95% CI |
|---|---|---|
| Active rTMS | 4 | |
| Sham TMS | 8 |
Last reviewed · How we verify
NCT04228276: VA-StARTS
Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation
Terminated
NA
Results posted
Last updated 29 August 2025
What this trial tests
NA trial testing Repetitive transcranial magnetic stimulation (rTMS) in Stimulant Use Disorder in 30 participants. Terminated before completion.
Timeline
5 February 2021
Primary endpoint
30 April 2024
30 April 2024
1 June 2024
Quick facts
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 5 February 2021 |
| Primary completion | 30 April 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Repetitive transcranial magnetic stimulation (rTMS)
Conditions studied
- Stimulant Use Disorder — all drugs for Stimulant Use Disorder →
- Substance-related Disorders — all drugs for Substance-related Disorders →
Sponsor
VA Office of Research and Development — full company profile →
Who can join
Adults 18 to 65, any sex, with Stimulant Use Disorder or Substance-related Disorders. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Sponsor's own description
The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. rTMS may be a promising treatment option for SUD. In this study, we will demonstrate the feasibility of applying rTMS to Veterans with SUD, examine the efficacy of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04228276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Repetitive transcranial magnetic stimulation (rTMS)
Trials testing the same drug.
- NCT07112105 — Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder · NA · not yet recruiting
- NCT07474974 — ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive D · NA · not yet recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
- NCT05964192 — Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Trea · NA · recruiting
Other recruiting trials for Stimulant Use Disorder
Currently open trials in the same condition.
- NCT05958017 — reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA) · NA · recruiting
- NCT06790576 — Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder · Phase 1 · recruiting
- NCT06513156 — Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use · NA · recruiting
- NCT06444256 — Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder · Phase 2 · recruiting
- NCT06323837 — Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treat · Phase 2 · recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
- NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care · Phase 1 · not yet recruiting
- NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran · NA · not yet recruiting
- NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness · NA · not yet recruiting
- NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans · NA · not yet recruiting
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04228276 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04228276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing